In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

被引：41

作者：

Nunnally, Natalie S. ^{[1
]}

Etienne, Kizee A. ^{[1
]}

Angulo, David ^{[2
]}

Lockhart, Shawn R. ^{[1
]}

Berkow, Elizabeth L. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA

[2] Scynexis Inc, Jersey City, NJ USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 11期

关键词：

Candida glabrata; SCY-078; ibrexafungerp; FKS; echinocandins; resistance; antifungal; ECHINOCANDIN RESISTANCE; SURVEILLANCE; MK-3118;

D O I：

10.1128/AAC.01692-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant C. glabrata isolates.

引用

页数：4

共 50 条

[1] Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata
Ghannoum, M.
Long, L.
Isham, N.
Hager, C.
Wilson, R.
Borroto-Esoda, K.
Barat, S.
Angulo, D.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
[2] In vitro activity of SCY-078, a glucan synthase inhibitor, against blood isolates of Candida albicans, Candida parapsilosis, Candida glabrata and Candida krusei
Quindos, G.
Miranda-Cadena, K.
Linares-Sicilia, M. J.
Hernandez-Montesinos, M. I.
Sanchez-Reus, F.
Vidal-Garcia, M.
Lopez-Soria, L. M.
Rezusta, A.
San-Millan, R.
Marcos-Arias, C.
Jauregizar, N.
Eraso, E.
MYCOSES, 2017, 60 : 212 - 213
[3] In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris
Berkow, Elizabeth L.
Angulo, David
Lockhart, Shawn R.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (07)
[4] Ibrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R.
Donnelley, M. A.
Thompson, G. R., III
MEDICAL MYCOLOGY, 2020, 58 (05) : 579 - 592
[5] Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
Arendrup, Maiken Cavling
Perlin, David S.
Jensen, Rasmus Hare
Howard, Susan Julie
Goodwin, Joanne
Hope, William
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2435 - 2442
[6] Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
Gamal, Ahmed
Chu, Sherman
McCormick, Thomas S.
Borroto-Esoda, Katyna
Angulo, David
Ghannoum, Mahmoud A.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
[7] Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)
Zhu, Y. C.
Barat, S. A.
Borroto-Esoda, K.
Angulo, D.
Chaturvedi, S.
Chaturvedi, V.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)
[8] Identification of Candida glabrata mutants with altered sensitivity to caspofungin, a β-glucan synthase inhibitor
Rosenwald, A.
Arora, G. S.
Ferrandino, R. M.
Gerace, E. L.
Mohammednetej, M.
Nosair, W.
Rattila, S.
Zirzow, A. C.
Rolfes, R. J.
MOLECULAR BIOLOGY OF THE CELL, 2015, 26
[9] The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
Judith Marcos-Zambrano, Laura
Gomez-Perosanz, Marta
Escribano, Pilar
Bouza, Emilio
Guinea, Jesus
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 1969 - 1976
[10] In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei
M. Drago
M. M. Scaltrito
G. Morace
European Journal of Clinical Microbiology and Infectious Diseases , 2004, 23 : 619 - 624

← 1 2 3 4 5 →